Triton 2 Patient Summary
TRITON2 Clinical Trial
This is for patients with surgical or medically castrated metastatic prostate cancer that is progressing following treatment with Zytiga, Xtandi, and taxane based chemotherapy.
Patients with tumors associated with BRAC1, BRACA2, or ATM gene mutations or alterations but will be placed in one arm if the presence of tumor spread beyond the prostate gland can be identified. Patients with BRACA1,BRACA2, or ATM genetic mutations or alterations will be placed in another arm if the presence of tumor spread beyond the prostate gland cannot be identified. A third study arm will include patients with tumors that are associated with other types of genetic mutations or alterations.
Potential Patient Benefits: Increased survival in patients with metastatic hormone resistant prostate cancer.
Potential Patient Risks: Rucaparib will have no effect on tumor progression or extending survival. Side effects following use of rucaparib are also possible.
Organization: Clovis Oncology, Inc.